This suggests that SHP2 may act as a negative regulator in these pathways, counteracting the effects of CD244 and potentially alleviating its pro-inflammatory and pro-apoptotic activities in the context of COPD. This evidence concerns the gene CD244 and chronic obstructive pulmonary disease.